On August 22, Phase II of Jiangsu (Yangtze River) New Medicine Development Institute, a major R&D institution in biological medicine field and key layout and deployment project of Jiangsu "11th Five-Year Plan", passed the expert argumentation. It marked that Phase I of the Institute was basically completed, and Phase II officially started. It also indicated that the Institute construction has made the important progress towards the goal for being the internationally advanced and domestically leading institute.
The Argumentation Meeting attendees included, (of Jiangsu Science and Technology Department) Jing Mao, Director of Condition Division, Zhao Jianguo, Director of Planning Division, Dr. Li Taisheng from Condition Division; (of Taizhou Science and Technology Bureau) Xu Shuping, Director of Bureau, Zhao Bin, Director of High-tech Division; (of YRPG) Vice General Manager Sun Tianjiang, and principals of institutions. The total of seven experts proved the planning feasibility of Phase II of the Institute, such as Lin Guojiang, academician of Shanghai Institute of Organic Chemistry of Chinese Academy of Sciences, and Zhang Luyong, professor of Chinese Pharmaceutical University.
The Institute, one of twenty major Jiangsu construction projects of R&D institutions initiated in 2006, was supported by YRPG in construction. The Institute, focusing on the innovation development in the biological medicine industry, aims to construct the domestically first-class drug innovation talent team and R&D platform, to carry out with strategic and prospective research of industrial technology as well as major target product development, and to lead the technology innovation and industry upgrading, so as to provide core technical support for technology spanning and structure adjustment of Jiangsu pharmaceutical industry. Phase I of the Institute took three years in its construction with the investment of RMB 121 million, and has completed the initial construction of the research centers on traditional Chinese medicine manufacturing process, drug preparation, chemical drug R&D, and biological drug R&D. Phase I of the Institute has the R&D sites of 3850 m² and the innovative team of more than 200 members. The Institute has the applied invention patents of 24 and the authorized invention patents of 7, which was essential for the Institute to be listed as the national enterprise technology center and national key laboratory of a drug preparation technology, and also qualified YRPG as the national innovation enterprise of the first batch.
Phase II of the Institute stresses high-level innovative talents introduction and innovation team construction, and it will construct the relevant R&D facilities such as Drug Effect and Metabolism Research Center, Analysis and Test Research Center, and Pilot Research Center, and will build several joint laboratories with the domestic key science and education units. Phase II of the Institute has a total investment of RMB 155 million and is scheduled to complete by 2011.When Phase II is completed, the Institute will cover an area of 300 mu, have 2 R&D buildings of 32000 square meters, and introduce a number of international high-level talents with the professional R&D team of 300 persons.
On the Argumentation Meeting, experts highly praised the work ideas and implement measures of Phase II construction, unanimously believed that the construction of high-level innovation team and R&D platform would greatly improve the innovative ability of the Institute, help to upgrade YRPG products, improve core competitiveness of innovative drugs and related industry, and even exert important influence for Taizhou Pharmaceutical City promotion, Jiangsu and national pharmaceutical great-leap-forward development and improvement.
Attendees visited YRPG Institute, New Medicine Development Institute under construction, the subsidiary Haici Biological Pharmaceutical Co., Ltd., and Emulsion Production Workshop.